结核病领域研究进展(2020年度)

doi:10.3969/j.issn.1000-6621.2021.01.003

摘要/Abstract

摘要：

结核病是严重危害人类健康的传染性疾病之一,是全球单一传染病致死的十大死亡原因之一。2020年全球结核病研究领域学者做出了诸多努力,在结核病基础、诊断、治疗和预防等方面研究均有很多突破。这些突破给结核病防治科技工作者带来了很多的启发和思路,也为临床治疗带来了更多的希望,例如:结核分枝杆菌Sulfolipid-1的致咳机制研究带来了控制结核分枝杆菌传染的新思路;M72/AS01_E疫苗的良好保护效果让我们看到继卡介苗之后的新希望;Nix-TB的研究结果为复治或难治耐多药/广泛耐药结核病(MDR/XDR-TB)患者带来了新的曙光;mRNA标记物等新型诊断方法研究也在不断取得进步。为了提高全国结核病防治人员的诊疗能力,及时了解全球结核病研究在新技术、新方法、新理念和新药物研发上的突破,中国防痨协会组织专家对2019年10月至2020年10月于国际上发表的重要文献进行解读,以期为推动我国结核病领域研究工作做出贡献。

关键词: 分枝杆菌,结核, 研究类型, 综述文献(主题)

Abstract:

Tuberculosis (TB) is one of the most serious infectious diseases, and one of the top ten death causes of single infectious disease globally. In 2020, researchers have made many efforts, and many breakthroughs have been made in basic research, diagnosis, treatment and prevention on TB. These breakthroughs have brought a lot of inspiration and ideas to TB research, and also brought more hope for clinical work. For example, the research on the cough mechanism of MTB sulfolipid-1 has brought new ideas to control the infection of MTB. The good protective effect of M72/AS01_E vaccine gave us hope for TB prevention after BCG. The results of the Nix-TB study bring new light to the retreated or refractory MDR/XDR-TB patients. New diagnostic methods such as mRNA markers are also making progress. In order to improve the diagnosis and treatment ability of national TB prevention and control personnel, and timely understand the breakthrough of global TB research in new technologies, new methods, new concepts and new drug research, Chinese Antituberculosis Association organized experts to interpret the important literatures published internationally from October 2019 to October 2020, so as to contribute to promoting the research work in the field of TB in China.

Key words: Mycobacterium tuberculosis, Study characteristics, Review literature as topic

中国防痨协会. 结核病领域研究进展(2020年度)[J]. 中国防痨杂志, 2021, 43(1): 6-11. doi: 10.3969/j.issn.1000-6621.2021.01.003

Chinese Antituberculosis Association. Tuberculosis research progress in 2020[J]. Chinese Journal of Antituberculosis, 2021, 43(1): 6-11. doi: 10.3969/j.issn.1000-6621.2021.01.003

参考文献 36

[1]	Moreira-Teixeira L, Tabone O, Graham CM, et al. Mouse transcriptome reveals potential signatures of protection and pathogenesis in human tuberculosis. Nat Immunol, 2020,21(4):464-476. doi: 10.1038/s41590-020-0610-z. doi: 10.1038/s41590-020-0610-z URL pmid: 32205882
[2]	Plumlee CR, Duffy FJ, Gern BH, et al. Ultra-low Dose Aerosol Infection of Mice with Mycobacterium tuberculosis More Closely Models Human Tuberculosis[J/OL]. Cell Host Microbe, 2020[2020-12-14]. doi: 10.1016/j.chom.2020.10.003.Online ahead of print.
[3]	Wang L, Wu J, Li J, et al. Host-mediated ubiquitination of a mycobacterial protein suppresses immunity. Nature, 2020,577(7792):682-688. doi: 10.1038/s41586-019-1915-7. doi: 10.1038/s41586-019-1915-7 URL pmid: 31942069
[4]	Huang H, Wang C, Rubelt F, et al. Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening. Nat Biotechnol, 2020,38(10):1194-1202. doi: 10.1038/s41587-020-0505-4. doi: 10.1038/s41587-020-0505-4 URL pmid: 32341563
[5]	Khan N, Downey J, Sanz J, et al. M.tuberculosis Reprograms Hematopoietic Stem Cells to Limit Myelopoiesis and Impair Trained Immunity. Cell, 2020, 183(3): 752-770.e22. doi: 10.1016/j.cell.2020.09.062. doi: 10.1016/j.cell.2020.09.062 URL pmid: 33125891
[6]	Ji DX, Yamashiro LH, Chen KJ, et al. Type Ⅰ interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra. Nat Microbiol, 2019,4(12):2128-2135. doi: 10.1038/s41564-019-0578-3. doi: 10.1038/s41564-019-0578-3 URL pmid: 31611644
[7]	Scheuermann L, Pei G, Domaszewska T, et al. Platelets Restrict the Oxidative Burst in Phagocytes and Facilitate Primary Progressive Tuberculosis. Am J Respir Crit Care Med, 2020,202(5):730-744. doi: 10.1164/rccm.201910-2063OC. doi: 10.1164/rccm.201910-2063OC URL pmid: 32421376
[8]	Wang Q, Boshoff HIM, Harrison JR, et al. PE/PPE proteins mediate nutrient transport across the outer membrane of Mycobacterium tuberculosis. Science, 2020,367(6482):1147-1151. doi: 10.1126/science.aav5912. doi: 10.1126/science.aav5912 URL pmid: 32139546
[9]	Rempel S, Gati C, Nijland M, et al. A mycobacterial ABC transporter mediates the uptake of hydrophilic compounds. Nature, 2020,580(7803):409-412. doi: 10.1038/s41586-020-2072-8. doi: 10.1038/s41586-020-2072-8 URL
[10]	Zhang L, Zhao Y, Gao Y, et al. Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol. Science, 2020,368:1211-1219. doi: 10.1126/science.aba9102. doi: 10.1126/science.aba9102 URL pmid: 32327601
[11]	Guo H, Courbon GM, Bueler SA, et al. Structure of mycobacterial ATP synthase bound to the tuberculosis drug bed-aquiline[J/OL]. Nature, 2020[2020-12-14]. doi: 10.1038/s41586-020-3004-3. Online ahead of print.
[12]	Gupta RK, Turner CT, Venturini C, et al. Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. Lancet Respir Med, 2020,8(4):395-406. doi: 10.1016/s2213-2600(19)30282-6. doi: 10.1016/S2213-2600(19)30282-6 URL pmid: 31958400
[13]	Turner CT, Gupta RK, Tsaliki E, et al. Blood transcriptional biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective, observational, diagnostic accuracy study. Lancet Respir Med, 2020,8(4):407-419. doi: 10.1016/s2213-2600(19)30469-2. doi: 10.1016/S2213-2600(19)30469-2 URL pmid: 32178775
[14]	Ahmad R, Xie L, Pyle M, et al. A rapid triage test for active pulmonary tuberculosis in adult patients with persistent cough. Sci Transl Med, 2019, 11(515): eaaw8287. doi:10.1126/scitranslmed.aaw8287. doi: 10.1126/scitranslmed.aaw8287 URL pmid: 31645455
[15]	Eloi P, Nascimento GA, Córdula C, et al. Toward a point-of-care diagnostic for specific detection of Mycobacterium tuberculosis from sputum samples. Tuberculosis (Edinb), 2020,121:101919. doi: 10.1016/j.tube.2020.101919. doi: 10.1016/j.tube.2020.101919 URL
[16]	Mishra H, Reeve BWP, Palmer Z, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study. The Lancet Respiratory Medicine, 2020,8:368-382. doi: 10.1016/s2213-2600(19)30370-4. doi: 10.1016/S2213-2600(19)30370-4 URL pmid: 32066534
[17]	Feuerriegel S, Kohl TA, Utpatel C, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex^®-MycTB[J/OL]. Eur Respir J, 2020[2020-12-14]. doi: 1183/13993003.01796-2020.
[18]	Divala TH, Fielding KL, Kandulu C, et al. Utility of broad-spectrum antibiotics for diagnosing pulmonary tuberculosis in adults: a systematic review and meta-analysis. Lancet Infect Dis, 2020,20(9):1089-1098. doi: 10.1016/s1473-3099(20)30143-2. doi: 10.1016/S1473-3099(20)30143-2 URL pmid: 32437700
[19]	Ouchi Y, Mukai T, Koide K, et al. WQ-3810: A new fluoroquinolone with a high potential against fluoroquinolone-resis-tant Mycobacterium tuberculosis. Tuberculosis (Edinb), 2020,120:101891. doi: 10.1016/j.tube.2019.101891. doi: 10.1016/j.tube.2019.101891 URL
[20]	de Jager VR, Dawson R, van Niekerk C, et al. Telacebec (Q203), a New Antituberculosis Agent. N Engl J Med, 2020,382(13):1280-1281. doi: 10.1056/NEJMc1913327. doi: 10.1056/NEJMc1913327 URL pmid: 32212527
[21]	Abidi S, Achar J, Assao Neino MM, et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J, 2020,55(3):1901467. doi: 10.1183/13993003.01467-2019. doi: 10.1183/13993003.01467-2019 URL pmid: 31862767
[22]	Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 2020,382(10):893-902. doi: 10.1056/NEJMoa1901814. doi: 10.1056/NEJMoa1901814 URL pmid: 32130813
[23]	Franke MF, Khan P, Hewison C, et al. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid: A Prospective Multi-country Study[J/OL]. Am J Respir Crit Care Med, 2020[2020-12-14]. doi: 10.1164/rccm.202001-0135OC. Online ahead of print.
[24]	Olayanju O, Esmail A, Limberis J, et al. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. Eur Respir J, 2020,55(1):1901181. doi: 10.1183/13993003.01181-2019. doi: 10.1183/13993003.01181-2019 URL pmid: 31619478
[25]	Blanc FX, Badje AD, Bonnet M, et al. Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults. N Engl J Med, 2020,382(25):2397-2410. doi: 10.1056/NEJMoa1910708. doi: 10.1056/NEJMoa1910708 URL pmid: 32558469
[26]	Ordonez AA, Wang H, Magombedze G, et al. Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. Nat Med, 2020,26(4):529-534. doi: 10.1038/s41591-020-0770-2. doi: 10.1038/s41591-020-0770-2 URL pmid: 32066976
[27]	Ravenscroft L, Kettle S, Persian R, et al. Video-observed therapy and medication adherence for tuberculosis patients: randomised controlled trial in Moldova. Eur Respir J, 2020,56(2):2000493. doi: 10.1183/13993003.00493-2020. doi: 10.1183/13993003.00493-2020 URL pmid: 32381495
[28]	Schrager LK, Vekemens J, Drager N, et al. The status of tuberculosis vaccine development. Lancet Infect Dis, 2020,20(3):e28-e37. doi: 10.1016/S1473-3099(19)30625-5. doi: 10.1016/S1473-3099(19)30625-5 URL pmid: 32014117
[29]	Tait DR, Hatherill M, Van Der Meeren O, et al. Final Analysis of a Trial of M72/AS01_E Vaccine to Prevent Tuberculosis. N Engl J Med, 2019,381(25):2429-2439. doi: 10.1056/NEJMoa1909953. doi: 10.1056/NEJMoa1909953 URL pmid: 31661198
[30]	Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature, 2020,577(7788):95-102. doi: 10.1038/s41586-019-1817-8. doi: 10.1038/s41586-019-1817-8 URL pmid: 31894150
[31]	Gupta RK, Calderwood CJ, Yavlinsky A, et al. Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nat Med, 2020,26(12):1941-1949. doi: 10.1038/s41591-020-1076-0. doi: 10.1038/s41591-020-1076-0 URL pmid: 33077958
[32]	World Health Organization. WHO consolidated guidelines on tuberculosis preventive treatment. Geneva: World Health Organization, 2020.
[33]	Huang CC, Becerra MC, Calderon R, et al. Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis. Am J Respir Crit Care Med, 2020,202(8):1159-1168. doi: 10.1164/rccm.201908-1576OC. doi: 10.1164/rccm.201908-1576OC URL pmid: 32551948
[34]	Ganmaa D, Uyanga B, Zhou X, et al. Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease. N Engl J Med, 2020,383:359-368. doi: 10.1056/NEJMoa1915176. doi: 10.1056/NEJMoa1915176 URL pmid: 32706534
[35]	Theron G, Limberis J, Venter R, et al. Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis. Nat Med, 2020,26(9):1435-1443. doi: 10.1038/s41591-020-0940-2. doi: 10.1038/s41591-020-0940-2 URL pmid: 32601338
[36]	Ruhl CR, Pasko BL, Khan HS, et al. Mycobacterium tuberculosis Sulfolipid-1 Activates Nociceptive Neurons and Induces Cough. Cell, 2020, 181(2): 293-305.e11. doi: 10.1016/j.cell.2020.02.026. doi: 10.1016/j.cell.2020.02.026 URL pmid: 32142653